United States Food and Drug Administration (USFDA) has concluded inspection at Bharat Parenterals’ subsidiary – Innoxel Lifesciences’ finished dosage manufacturing facility in Vadodara, Gujarat. The inspection of the General Injectables Block was conducted from April 13, 2026 to April 17, 2026 and April 20, 2026.
At the conclusion of the inspection, the USFDA has issued five observations under a Voluntary Action Indicated (VAI) classification. The final Establishment Inspection Report (EIR) is awaited.
The General Injectables Block is a key manufacturing facility supporting the supply of sterile injectable formulations to regulated markets, including the United States and the European Union.
Bharat Parenterals is engaged in to the business of the Pharmaceuticals & Drugs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: